Abstract:Background: An increase in deaths has been perceived during the pandemic, which cannot be explained only by COVID-19. The actual number of deaths far exceeds the recorded data on deaths directly related to SARS-CoV-2 infection. Data from early and short-lived pandemic studies show a dramatic shift in cardiovascular mortality. Grounded in the post-pandemic era, macroscopic big data on cardiovascular mortality during the pandemic need to be further reviewed and studied, which is crucial for cardiovascular disease prevention and control. Methods: We retrieved and collected data associated with cardiovascular disease mortality from the National Vital Statistic System from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform based on the ICD-10 codes. We applied regression analysis to characterize overall cardiovascular disease mortality trends from 2010 to 2023 and built a time series model to predict mortality for 2020–2023 based on mortality data from 2010 to 2019 in order to affirm the existence of the excess deaths by evaluating observed vs. predicted mortality. We also conducted subgroup analyses by sex, age and race/ethnicity for the purpose of obtaining more specific sociodemographic information. Results: All-cause age-standardised mortality rates (ASMRs) for CVD dramatically increased between 2019 and 2021[annual percentage change (APC) 11.27%, p < 0.01], and then decreased in the following 2021–2023(APC: −7.0%, p < 0.01). Subgroup analyses found that the ASMR change was most pronounced in Alaska Indians/Native American people (APC: 16.5% in 2019–2021, −12.5% in 2021–2023, both p < 0.01), Hispanics (APC: 12.1% in 2019–2021, −12.2% in 2021–2023, both p < 0.05) and non-Hispanic Black people (APC:11.8% in 2019–2021, −10.3% in 2021–2023, both p < 0.01)whether during the increasing or declining phase. Similarly, the ASMR change was particularly dramatic for the 25–44 age group (APC:19.8% in 2019–2021, −15.4% in 2021–2023, both p < 0.01) and males (APC: 11.5% in 2019–2021, −7.6% in 2021–2023, both p < 0.01). By the end of 2023, the proportion of COVID-related excess death remained high among the elderly (22.4%), males (42.8%) and Alaska Indians/Native American people(39.7%). In addition, we did not find the presence of excess deaths in the young (25–44) and middle-aged cohort (45–64) in 2023, while excess deaths remained persistent in the elderly. Conclusions: All-cause ASMRs for CVD increased notably during the initial two years of the COVID-19 pandemic and then witnessed a decline in 2021–2023. The cohorts (the young, males and minorities) with the steepest rise in mortality decreased at the fastest rate instead. Previous initiatives to promote cardiovascular health were effective, but further research on cardiovascular healthcare for the elderly and racial disparities should be attached to priority considering the presence of sociodemographic differences in CVD death.

Cardiovascular presentations during the COVID-19 pandemic: an interrupted time series analysis

Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic

An Interrupted Time-Series Analysis of the Impact of COVID-19 on Hospitalizations for Vascular Events in 3 Canadian Provinces

Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19

Impact of COVID-19 pandemic on cardiovascular diseases hospitalisation, management and mortality in Switzerland

Impact of the COVID‐19 pandemic on provision of interventional cardiology and cardiac surgery services in Australia: a review of Medicare claims data

Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis

The impact of COVID-19 pandemic on cardiovascular diseases hospitalization, management and mortality in Switzerland

Changes in the care of acute cerebrovascular and cardiovascular conditions during the first year of the covid-19 pandemic in 746 hospitals in the USA: retrospective analysis

Impact of the COVID-19 pandemic on cardiovascular mortality and contrast analysis within subgroups

Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Clinical outcomes for patients with cardiovascular diseases before, during, and after the COVID19 pandemic. A pooled analysis of 600.000 patients.

Impact of COVID-19 Induced Lockdown on the OPD Patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and Oncology in India- A Cross-Sectional Research Study

Low and Delayed Patient Arrival Rates during COVID-19 Pandemic in Acute Coronary Syndrome Patients: A Study from Tertiary Cardiac Center

Changes in ischemic stroke presentations, management and outcomes during the first year of the COVID-19 pandemic in Alberta: a population study

Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020)

Influence of COVID-19 pandemic in India on coronary artery disease clinical presentation, angiography, interventions and in-hospital outcomes: a single centre prospective registry-based observational study

Impact of the COVID-19 Pandemic Lockdown on Hospitalizations for Cerebrovascular Disease and Related In-Hospital Mortality in China: A Nationwide Observational Study

Abstract 11754: Trends in Cardiovascular Mortality Before and During the COVID-19 Pandemic

Trends and Characteristics of COVID-19 and Cardiovascular Disease Related Studies